Finepoint Capital LP

Name: Finepoint Capital LP 13F holdings, Q1 2025
Creator: Finepoint Capital LP
Published: 2025-05-14

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q4 2024Q3 2024Q2 2024Q1 2024

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), Finepoint Capital LP reported 19 stock positions worth $592.5 million. Its top holding was Qxo (QXO) at 55.9% of the portfolio, followed by Liberty Broadband-C (LBRDK, 7.6%) and Springworks Therapeutics (SWTX, 5.4%). Compared with Q4 2024, it sold out of 1 and reduced 17. The biggest sale was Liberty Broadband-C (LBRDK, shares −74%).

Most Recent 13F: Q2 2026
Location: BOSTON, MA
CIK: 0001608126
Portfolio Value: $592.5M (Q1 2025)
SEC Filing: 0000904454-25-000272 ↗ filed May 14, 2025

Holdings Value

Holdings 19 stocks · $592.5M


QXO Qxo Inc.	55.91%	24,468,160	$331.3M	Reduce -1.9%
LBRDK Liberty Broadband-C	7.60%	529,240	$45.0M	Reduce -73.7%
SWTX Springworks Therapeutics Inc.	5.43%	728,602	$32.2M	Reduce -2.7%
LLYVK Liberty Media Corp.-Liberty-C	4.98%	432,895	$29.5M	Reduce -46.7%
ASND Ascendis Pharma A/S	4.73%	179,872	$28.0M	Reduce -2.7%
RVMD Revolution Medicines Inc.	4.13%	691,260	$24.4M	Reduce -2.7%
MLTX Moonlake Immunotherapeutics	2.87%	435,785	$17.0M	Reduce -2.7%
LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV	2.78%	656,587	$16.5M	Reduce -2.7%
CYTK Cytokinetics Inc.	2.10%	309,948	$12.5M	Reduce -2.7%
RNAM Avidity Biosciences Inc.	1.90%	380,700	$11.2M	Reduce -2.7%
SRPT Sarepta Therapeutics Inc.	1.70%	157,555	$10.1M	Reduce -2.7%
PRTA Prothena Corp. PLC	1.34%	640,071	$7.9M	Reduce -2.6%
XNCR Xencor Inc.	1.15%	642,200	$6.8M	Reduce -2.7%
EYPT Eyepoint Inc.	0.99%	1,081,954	$5.9M	Reduce -2.6%
RLAY Relay Therapeutics Inc.	0.94%	2,117,646	$5.5M	Reduce -2.7%
ARVN Arvinas Inc.	0.82%	694,028	$4.9M	Reduce -2.8%
SLDB Solid Biosciences Inc.	0.60%	961,251	$3.6M	No change
ANNA Aleanna Inc.	0.04%	27,717	$209K	No change
CLDI Calidi Biotherapeutics Inc.	0.00%	12,499	$7K	Reduce -0.0%

Options reported separately and not counted above: SPY puts ($422.2M), IWM puts ($296.3M).

Other holdings (4): bonds, preferreds, convertibles and warrants · $293K (not counted above)

Security	Class	Shares / Principal	Value	Change
ANNAW Aleanna Inc. Class A - 29	*W EXP 12/13/202	490,000	$122K	No change
GATEW Marblegate Acquisition -CW22	*W EXP 08/31/202	735,000	$118K	No change
MNYWW Moneyhero Ltd.-28	*W EXP 09/13/202	895,000	$33K	No change
LAKESHORE BIOPHARMA CO LTD	*W EXP 03/15/202	489,999	$20K	No change

Total filed on the 13F, all lines: $592.8M.

Portfolio Sells Q4 2024 → Q1 2025


LBRDK Liberty Broadband-C	Reduce -73.7%	7.60%	−9.79
ARGX Argenx SE - ADR	Sold out	0.00%	−3.76
LLYVK Liberty Media Corp.-Liberty-C	Reduce -46.7%	4.98%	−1.40
ARVN Arvinas Inc.	Reduce -2.8%	0.82%	−0.76
XNCR Xencor Inc.	Reduce -2.7%	1.15%	−0.60
SRPT Sarepta Therapeutics Inc.	Reduce -2.7%	1.70%	−0.57
RLAY Relay Therapeutics Inc.	Reduce -2.7%	0.94%	−0.10
CLDI Calidi Biotherapeutics Inc.	Reduce -0.0%	0.00%	−0.00
EYPT Eyepoint Inc.	Reduce -2.6%	0.99%	+0.03
MLTX Moonlake Immunotherapeutics	Reduce -2.7%	2.87%	+0.07
PRTA Prothena Corp. PLC	Reduce -2.6%	1.34%	+0.29
CYTK Cytokinetics Inc.	Reduce -2.7%	2.10%	+0.37
RVMD Revolution Medicines Inc.	Reduce -2.7%	4.13%	+0.54
RNAM Avidity Biosciences Inc.	Reduce -2.7%	1.90%	+0.58
LKFT Lakefront Biotherapeutic-ADR	Reduce -2.7%	2.78%	+0.64
ASND Ascendis Pharma A/S	Reduce -2.7%	4.73%	+1.79
SWTX Springworks Therapeutics Inc.	Reduce -2.7%	5.43%	+2.31
QXO Qxo Inc.	Reduce -1.9%	55.91%	+10.17

Portfolio Buys Q4 2024 → Q1 2025


None this quarter.

All Filings

Quarter	Positions	13F Reported Value	Top Holdings
Q2 2026	4	$460.8M	QXO, RXO, ANNA, CLDI
Q1 2026	4	$416.6M	QXO, RXO, ANNA, CLDI
Q4 2025	5	$532.7M	QXO, RXO, SLDB, ANNA, CLDI
Q3 2025	5	$542.8M	QXO, RXO, SLDB, ANNA, CLDI
Q2 2025	5	$504.1M	QXO, LLYVK, SLDB, ANNA, CLDI
Q1 2025	19	$592.5M	QXO, LBRDK, SWTX, LLYVK, ASND
Q4 2024	20	$866.7M	QXO, LBRDK, LLYVK, ARGX, RVMD
Q3 2024	18	$822.2M	QXO, LBRDK, RVMD, ARGX, ASND
Q2 2024	17	$351.8M	LBRDK, RVMD, ASND, SWTX, ARGX
Q1 2024	17	$376.0M	LBRDK, SWTX, ASND, ARVN, RVMD